Patients with chronic obstructive pulmonary disease (COPD) have multiple breathing problems and, at the more severe stages, experience acute exacerbations of COPD up to three times annually. Because ...
6 August2012, USA California (Acedrugstore.com): An experimental and novel lung medication with is a combination drug of LAMA/LABA and produced by GlaxoSmithKline and Theravance pharmaceutical ...
Bronchodilators are the cornerstone of pharmacological management of chronic obstructive pulmonary disease (COPD), and current guidelines recommend their use as first-line therapy in symptomatic ...
April 14, 2020--Clinicians grappling with the pharmacologic management of COPD in patients complaining of exercise intolerance or dyspnea now have new guidance. The American Thoracic Society has ...
GSK and Theravance Announce Positive Results From Four Pivotal Phase III Studies for Once-Daily LAMA/LABA (UMEC/VI) in COPD Headline Results From the Pivotal Efficacy Studies Support Intention to ...
Overall results demonstrated that for the LABA/LAMA cohort cardiovascular event frequency was 2.11% compared to 3.41% in the LABA/ICS cohort. According to a new study published in the Annals of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results